Home > Insider Trading > Filing (0001209191-19-021014)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1690585	Magenta Therapeutics Inc.	MGTA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1451612	Bruce Booth	C/O Magenta Therapeutics, Inc. 100 Technology Sq, 5Th Floor Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-03-20	726,500	$0.00	4,117,125	No	4	J	Indirect	See Footnote
Common Stock	Acquisiton	2019-03-20	14,245	$0.00	14,245	No	4	J	Indirect	See Footnote
Common Stock	Disposition	2019-03-20	14,245	$17.86	0	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	J	Indirect	See Footnote
No	4	J	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. ("AVF X") to its general partner and limited partners without additional consideration.
The shares are held directly by AVF X. The general partner of AVF X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by AVF X and AVA X LP, except to the extent of his pecuniary interest therein, if any.
Represents the shares received by AVA X LP in connection with the pro rata distribution described in footnote 1 by AVF X.
The shares are held directly by AVA X LP. AVA X LLC is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by AVF X and AVA X LP, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold by AVA X LP in multiple transactions at prices ranging from $17.75 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.